01505nam a2200265 4500 ESSALUD 20260902150847.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Spyropoulos, Alex C. Autor 54428 Advanced Therapy for Intermediate-Risk Pulmonary Embolism páginas: 2052-2054 Pulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally. The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago. Patients with high-risk pulmonary embolism and cardiogenic shock appear to benefit from early thrombus removal, with rapid reductions in pulmonary obstruction and pulmonary vascular resistance from baseline and a lower risk of death than with anticoagulation alone, but at the cost of a nearly 10% risk of major bleeding. ANTICOAGULACIÓN 53834 TROMBOEMBOLISMO 32218 CARDIOLOGÍA 11301 NEUMOLOGÍA 25628 MEDICINA CLÍNICA HOSPITALARIA 53754 RADIOLOGÍA GENERAL 54381 Vedantham, Suresh 53896 22717 22665 Massachusetts NEJM Group NEJM013 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-28 sqb 22891 22891